Stock Price
14.51
Daily Change
-0.09 -0.62%
Monthly
7.48%
Yearly
27.84%
Q1 Forecast
14.47

Amarin reported $49.67M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
Amarin USD 49.67M 23.07M Sep/2025
AstraZeneca USD 15.19B 733M Sep/2025
DBV Technologies USD 2.77M 1.31M Sep/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Halozyme Therapeutics USD 354M 148M Sep/2025
Ionis Pharmaceuticals USD 157M 295M Sep/2025
Neurocrine Biosciences USD 794.9M 107.4M Sep/2025
Novartis USD 13.91B 144M Sep/2025